HARP stock forecast
Our latest prediction for Harpoon Therapeutics, Inc.'s stock price was made on the Aug. 19, 2020 when the stock price was at 11.63$.
In the short term (2weeks), HARP's stock price should underperform the market by -1.27%. During that period the price should oscillate between -10.72% and +12.79%.
In the medium term (3months), HARP's stock price should underperform the market by -2.53%. During that period the price should oscillate between -39.89% and +31.43%.Get email alerts
Create a solid portfolio with HARP
About Harpoon Therapeutics, Inc.
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
At the moment the company generates 10M USD in revenues.
On its last earning announcement, the company reported a loss of -2.27$ per share.
The book value per share is -2.20$
Three months stock forecastAug. 19, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|